Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

AMRN Jan 2024 7.000 put

OPR - OPR Delayed Price. Currency in USD
5.410.00 (0.00%)
As of 01:48PM EST. Market open.
Advertisement
Full screen
Previous Close5.41
Open5.33
Bid3.00
Ask6.00
Strike7.00
Expire Date2024-01-19
Day's Range5.33 - 5.41
Contract RangeN/A
Volume16
Open Interest30
  • Zacks

    Why Amarin (AMRN) Stock Might be a Great Pick

    Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • Motley Fool

    Why Amarin Stock Was a Winner Today

    Before market open, Amarin announced that its Vazkepa (brand-named Vascepa in the U.S.) has been approved by Australia's Therapeutic Good Administration (TGA). Amarin didn't hesitate to mention that the Australian nod represents the fifth regulatory approval for Vazkepa/Vascepa. Among these jurisdictions are the U.S. and the European Union, which consists of 27 countries on that continent.

  • GlobeNewswire

    Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia

    -- VAZKEPA® Approved in Australia to Reduce the Risk of CV Events in Adult Statin-Treated Patients with High CV Risk with Elevated Triglycerides -- -- Marks Fifth Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets in 2022 -- DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Australia’s Therapeutic Good Administration (TGA) has granted approval to VAZKEPA (icosapent ethyl). The TGA appro

Advertisement
Advertisement